ABOUT MOLECULAR SENSING & BSI TECHNOLOGY
Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive detection technology for biophysical characterization of small molecule interactions with complex drug targets. This includes integral membrane proteins and biochemically intractable target binding assays in native-like, free-solution environments — no tags or tethering.
Conformational change is the hallmark of protein dynamics and is intimately related to protein function. BSI detects binding-induced target conformational change with high specificity and sensitivity. It allows unlabeled binding affinity measurement, target engagement verification and mechanism-of-action elucidation in a single assay platform, vital to informing pharmacology and medicinal chemistry drug discovery efforts.
MSI currently offers Drug Discovery Services to pharmaceutical companies and will begin shipments of BSI instrumentation in the
second half of 2014.
KEY APPLICATIONS OF BSI TECHNOLOGY
Direct binding quantification of low molecular weight ligands to ortho- and allosteric integral membrane protein and protein complex binding sites, under conditions where other technologies fail.
Direct binding confirmation of drug candidates from an HTS screen to the target of interest is critical to verification of a suspected MOA.
Complex drug targets for a large range of target classes have been successfully characterized in projects with major pharmaceutical companies.